Advertize Your Products on Indian-Commodity.com

Indian-commodity.com works out to be an optimum marketing platform for finance and investment market products, for we reach out to thousands of unique visitors daily. We do offer options of text links and text+image links on our website. You can opt for only home page link, or category page link, or category-wide links, or even full website links. Your site-wide or category-wide links, are listed on the old news articles as well. Sounds tempting!!

For any business queries or custom needs, please write us at advertise@indian-commodity.com

Biocon trades with traction on the bourses (24-Nov-2017)

Biocon is currently trading at Rs. 416.55, up by 3.50 points or 0.85% from its previous closing of Rs. 413.05 on the BSE.

The scrip opened at Rs. 416.00 and has touched a high and low of Rs. 419.35 and Rs. 414.00 respectively. So far 116235 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 427.95 on 21-Nov-2017 and a 52 week low of Rs. 283.03 on 24-Nov-2016.

Last one week high and low of the scrip stood at Rs. 427.95 and Rs. 385.05 respectively. The current market cap of the company is Rs. 24918.00 crore.

The promoters holding in the company stood at 60.67%, while institutions and non-institutions held 19.23% and 20.10% respectively.

Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.

KRABEVA, a monoclonal antibody (mAb) developed by Biocon, will help expand access to a world class, high quality biosimilar Bevacizumab for cancer patients in India. It is the world's first and only Bevacizumab with a unique 'Qual-Check' mechanism, which will ensure that patients get a quality-ascertained product right upto infusion.

Bevacizumab is indicated as a first-line treatment of patients with metastatic colorectal cancer (mCRC), and is accepted as a standard treatment option in combination with chemotherapy for patients with non-small-cell lung cancer (NSLC), metastatic renal cell carcinoma and recurrent ovarian cancer.

Biocon is India's largest and Asia's leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

(19-Mar-2018)

Tata Power Delhi Distribution (TPDDL), a joint venture (JV) of Tata Power and the Government of Delhi has launched artificial intelligence solution for Indian Discoms to make their operations smarter.......click on news to read complete article.

(19-Mar-2018)

Lupin has received final approval for its Desoximetasone Topical Spray, 0.25%, 30 ml, 50 ml, and 100 ml from the United States Food and Drug Administration (USFDA) to market a generic version of Taro Pharmaceuticals......click on news to read complete article.

(19-Mar-2018)

Most of the Asian equity indices are trading down in the early deals on Monday as caution gripped investors in a week in which the Federal Reserve is likely to hike US interest rates and perhaps signal......click on news to read complete article.

(17-Mar-2018)

The US markets closed modestly higher on Friday, with the S&amp;P 500 breaking a four-day losing streak after mostly upbeat economic data, though major indexes still suffered hefty weekly declines.......click on news to read complete article.

(17-Mar-2018)

The US markets closed modestly higher on Friday, with the S&amp;P 500 breaking a four-day losing streak after mostly upbeat economic data, though major indexes still suffered hefty weekly declines.......click on news to read complete article.

Disclaimer
By clicking on this page you accept all the terms and conditions framed by us.
News made available here are for informational purpose only. While utmost care
has been taken in providing the same. We claim no responsibility for its
accuracy. Readers of this blog who make their decision based on the information
posted here are solely responsible for their actions.